Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × alfatide II × Clear all

Phase

Phase 3 1 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 1

Interventions

Cyclophosphamide 552 pembrolizumab 430 Paclitaxel 392 Gemcitabine 373 Cisplatin 373 Carboplatin 369 Radiotherapy 330 fludarabine 314 Nivolumab 295 Bevacizumab 241 Docetaxel 239 Irinotecan 215 Magnetic Resonance Spectroscopy 210 Dexamethasone 197 Specimen Handling 193 Fluorouracil 192 Capecitabine 188 Cytarabine 180 Rituximab 176 fludarabine phosphate 172 Temozolomide 169 Oxaliplatin 169 Biopsy 169 Ipilimumab 164 Etoposide 158 Lenalidomide 157 Doxorubicin 150 Cetuximab 150 Radiation 145 Bortezomib 145

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02582801 2019-09-27

Clinical Research of 18F-Alfatide Ⅱ PET/CT in Breast Cancer

Jinling Hospital, China

Phase 1 Terminated

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡